Ibio Inc (IBIO)

$2.33 +0.04 (1.75%)
Market Cap 76.69M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.01
Volume 468,300
Avg Vol 6,853,344
Day's Range N/A - N/A
Shares Out 34.54M
Stochastic %K 57%
Beta 1.26
Analysts Strong Sell
Price Target $5.40

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
JPeanutBJelly
JPeanutBJelly Feb. 18 at 8:33 PM
$SGN SQUEEZE THE SHORTS! 🚀🔥 $IBRX $IBIO
0 · Reply
TreeShade
TreeShade Feb. 18 at 5:12 PM
$IBIO Slow, but upward ... due for news. Pretty big news. Breakout soon! 💸
1 · Reply
dcpanda
dcpanda Feb. 18 at 5:11 PM
$IBIO Come on break out already!!! Ive been adding so much 🤭
0 · Reply
TortillaDePatata
TortillaDePatata Feb. 18 at 4:44 PM
$IBIO You have to know something big is goig to happen, look at the institutional ownweship in the last month!!!
0 · Reply
TeresaRios416
TeresaRios416 Feb. 18 at 2:02 PM
$IBIO Biotech microcap with funding risk.
1 · Reply
Magglo
Magglo Feb. 18 at 6:04 AM
$IBIO Are there any events, presentations, or deadlines that can give the stock a boost? Otherwise, we'll continue to fall inexorably.
0 · Reply
Mortimer2020
Mortimer2020 Feb. 17 at 8:19 PM
$IBIO still trash...AI isn't saving them. It will take your money again w/o question...scam that never ends They will not turn the balance sheet. Bring back Tom at least he didn't hide it, "the secret sauce " guy... iBio, Inc. (IBIO) did not make a profit last year. For the fiscal year ended June 30, 2025, the company reported a net loss of approximately $18.38 million. Key financial results for the 2025 fiscal year (ending June 30, 2025) include: Net Loss: -$18.38 million. Operating Loss: -$18.6 million. Revenue: $0.4 million. Loss per share: -$1.75.
1 · Reply
WZMAN7227
WZMAN7227 Feb. 17 at 6:49 PM
$IBIO shooting blanks
0 · Reply
RiskKinetics
RiskKinetics Feb. 17 at 3:29 PM
$IBIO iBio develops biologics using its proprietary expression platform, with early-stage pipeline and partnership-dependent future.
0 · Reply
TaintMcBalls
TaintMcBalls Feb. 17 at 3:28 AM
This is the key to retirement Add to your watchlist $INTC $B $S $IBIO
0 · Reply
Latest News on IBIO
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:05 PM EST - 8 days ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 5 weeks ago

iBio Announces $26 Million Private Placement

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 3 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 3 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 3 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 4 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 4 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 5 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 6 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 6 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 6 months ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 8 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 8 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 8 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 10 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 10 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 10 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 10 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 11 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 3 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 3 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 3 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 3 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

JPeanutBJelly
JPeanutBJelly Feb. 18 at 8:33 PM
$SGN SQUEEZE THE SHORTS! 🚀🔥 $IBRX $IBIO
0 · Reply
TreeShade
TreeShade Feb. 18 at 5:12 PM
$IBIO Slow, but upward ... due for news. Pretty big news. Breakout soon! 💸
1 · Reply
dcpanda
dcpanda Feb. 18 at 5:11 PM
$IBIO Come on break out already!!! Ive been adding so much 🤭
0 · Reply
TortillaDePatata
TortillaDePatata Feb. 18 at 4:44 PM
$IBIO You have to know something big is goig to happen, look at the institutional ownweship in the last month!!!
0 · Reply
TeresaRios416
TeresaRios416 Feb. 18 at 2:02 PM
$IBIO Biotech microcap with funding risk.
1 · Reply
Magglo
Magglo Feb. 18 at 6:04 AM
$IBIO Are there any events, presentations, or deadlines that can give the stock a boost? Otherwise, we'll continue to fall inexorably.
0 · Reply
Mortimer2020
Mortimer2020 Feb. 17 at 8:19 PM
$IBIO still trash...AI isn't saving them. It will take your money again w/o question...scam that never ends They will not turn the balance sheet. Bring back Tom at least he didn't hide it, "the secret sauce " guy... iBio, Inc. (IBIO) did not make a profit last year. For the fiscal year ended June 30, 2025, the company reported a net loss of approximately $18.38 million. Key financial results for the 2025 fiscal year (ending June 30, 2025) include: Net Loss: -$18.38 million. Operating Loss: -$18.6 million. Revenue: $0.4 million. Loss per share: -$1.75.
1 · Reply
WZMAN7227
WZMAN7227 Feb. 17 at 6:49 PM
$IBIO shooting blanks
0 · Reply
RiskKinetics
RiskKinetics Feb. 17 at 3:29 PM
$IBIO iBio develops biologics using its proprietary expression platform, with early-stage pipeline and partnership-dependent future.
0 · Reply
TaintMcBalls
TaintMcBalls Feb. 17 at 3:28 AM
This is the key to retirement Add to your watchlist $INTC $B $S $IBIO
0 · Reply
1Powar
1Powar Feb. 16 at 2:37 AM
$IBIO genetic engineering in 2nd release Epstein files. Bitcoin created by DARPA with Epstein, iBio is DARPA. Run away or be with Satan. Thank you for your atten attention to this matter. GLTA
1 · Reply
chart_thirst
chart_thirst Feb. 15 at 7:31 PM
$IBIO some buys last week.
0 · Reply
WZMAN7227
WZMAN7227 Feb. 13 at 9:34 PM
$IBIO https://www.linkedin.com/posts/ibio-inc_hiring-invivo-pharmacology-activity-7428187836048113664-_zHT?utm_source=share&utm_medium=member_ios&rcm=ACoAABcnGdIBccvXqAqSYm1rjD19vQBtthG68oU
2 · Reply
smartmoney43
smartmoney43 Feb. 13 at 8:33 PM
$IBIO something brewing here
0 · Reply
Rower5oh
Rower5oh Feb. 13 at 2:47 PM
$IBIO LFG, Martin. Get this done!
1 · Reply
TaintMcBalls
TaintMcBalls Feb. 13 at 6:33 AM
$IBM $IBIO $IDEX $INO
0 · Reply
Techallure
Techallure Feb. 13 at 3:24 AM
$IBIO
0 · Reply
1Powar
1Powar Feb. 13 at 2:34 AM
$IBIO Bitcoin is DARPA. So is iBio. So is Facebook. The devil welcomes you and praises you for your greed. GLTA
1 · Reply
WZMAN7227
WZMAN7227 Feb. 13 at 12:36 AM
$IBIO https://www.google.com/search?q=IBIO+ELI+LILLY+HUB&rlz=1C1ONGR_enUS1171US1171&oq=IBIO+ELI+LILLY+HUB&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRigATIHCAUQIRigATIHCAYQIRiPAjIHCAcQIRiPAtIBCjEyMzg4ajBqMTWoAgmwAgHxBdv78ug6hh2O&sourceid=chrome&ie=UTF-8
1 · Reply
jmenger
jmenger Feb. 12 at 1:28 PM
$IBIO
1 · Reply
smartmoney43
smartmoney43 Feb. 12 at 1:05 AM
$IBIO solid 💪
0 · Reply
1Powar
1Powar Feb. 11 at 9:48 PM
$IBIO
1 · Reply